CQIP
Cancer Quality Improvement Program
HealthAlliance Hospital, Mary's Avenue Campus
6212130
Kingston, NY

Annual Report 2015
Cancer Program Total Case Volume, 2009 - 2013 My Facility

If Miscellaneous appears in your graph, note that this is a SEER-defined group. The exact primary sites and histologies included in this group may be found in the CQIP documentation.
Quality Measure Reports – Breast

- **BCSRT**: Breast radiation after breast conserving surgery (NQF 0219 – Accountability)
- **MAC**: Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 – Accountability)
- **HT**: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 – Accountability)
- **BCS**: Breast conserving surgery rate (Surveillance)
- **MASRT**: Radiation therapy recommended or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes (Accountability)
- **nBx**: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)

NQF = National Quality Forum Endorsed Measure
BREAST, 2013, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability)

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 11/02/2015)
Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. (CP3R data as of 11/02/2015)
Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. (CP3R data as of 11/02/2015)
BREAST, 2013, MASRT: Post-mastectomy radiation for women with 4 or more positive regional lymph nodes (Accountability)

Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes. (CP3R data as of 11/02/2015)

<table>
<thead>
<tr>
<th>Performance Rate</th>
<th>My Program</th>
<th>My State (NY)</th>
<th>My Census Region (Middle Atlantic)</th>
<th>My ACS Division (Eastern)</th>
<th>My CoC Program Type (CCP)</th>
<th>All CoC Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate</td>
<td>100 %</td>
<td>83 %</td>
<td>86.1 %</td>
<td>83.6 %</td>
<td>86.3 %</td>
<td>87.6 %</td>
</tr>
<tr>
<td>Denominator</td>
<td>3</td>
<td>522</td>
<td>1106</td>
<td>746</td>
<td>800</td>
<td>7473</td>
</tr>
<tr>
<td>95 % CI</td>
<td>(100.0,100.0)</td>
<td>(79.8,86.2)</td>
<td>(84.1,88.1)</td>
<td>(80.9,86.3)</td>
<td>(83.9,88.7)</td>
<td>(86.9,88.3)</td>
</tr>
</tbody>
</table>
BREAST, 2013, nBx: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer. (CP3R data as of 11/02/2015)